MA Market Consolidation

Rate compression produces consolidation. The relationship is mechanical: when payment rates decline or flatten, plans operating at the margin exit, plans seeking scale acquire, and new entrants identify gaps left by departing incumbents. The last time Medicare Advantage faced significant payment pressure, during the ACA-era benchmark reductions from 2010 through 2015, hundreds of plan contracts exited, enrollment temporarily declined for the first time in the program’s history, and the market restructured around fewer, larger entities that emerged from the contraction with stronger competitive positions. The CY 2027 rate environment carries the same structural dynamics at a fundamentally different scale. MA now covers 55% of Medicare beneficiaries, more than double the penetration during the ACA consolidation. The risk adjustment tightening is not a one-time benchmark cut that plans can absorb and grow past; it is a structural recalibration toward encounter-based RA that changes how plans generate revenue permanently. And the payvider model, which barely existed during ACA consolidation, now represents a viable alternative organizational form that may absorb share from departing standalone insurers.

Historical Precedent

#

The ACA reduced MA benchmarks to bring payments closer to FFS spending levels, phased in Star Ratings with quality bonus payments, and introduced the coding intensity adjustment. The combined effect produced the first sustained period of payment pressure the MA program had experienced. Between 2010 and 2015, the number of MA plan contracts available to beneficiaries declined substantially. CMS data showed a reduction from over 3,100 plan options in 2009 to approximately 2,400 by 2014. Many of the exiting plans were private fee-for-service plans that had operated without provider networks and relied on payment rates above FFS to attract enrollment. The coordinated care plans that survived, HMOs and PPOs with provider networks and care management infrastructure, emerged from the consolidation with higher enrollment concentration.

MA enrollment itself dipped briefly. After years of consistent growth, enrollment flattened in 2010 and 2011 before resuming its upward trajectory. By 2014, enrollment growth had returned to pre-ACA rates, and by 2017, the MA market was growing faster than it had before the benchmark reductions. The post-consolidation market was characterized by fewer but larger plans, richer benefits funded by a rebounding benchmark environment and coding-driven revenue growth, and a supplemental benefit arms race that attracted beneficiaries in record numbers. The carriers that survived the ACA consolidation, including UnitedHealth, Humana, and Aetna, used the post-contraction growth phase to build the enrollment bases they hold today.

Three features distinguish the current cycle from the ACA precedent. First, MA penetration is now over 55%, meaning the beneficiary population affected by plan exits, benefit reductions, and market restructuring is more than double the size it was during the ACA period. A plan exit that affected 50,000 beneficiaries in 2012 was a local disruption. A comparable exit in 2026 may affect 200,000 beneficiaries in the same geography because of intervening enrollment growth. The scale of potential disruption is structurally larger.

Second, the risk adjustment tightening is not cyclical. The ACA benchmark reductions were a one-time policy adjustment that plans could model, absorb, and eventually outgrow as medical cost trends and coding optimization restored margin. The current trajectory, V28 model reform, chart review exclusion, and the encounter-based RA future, changes the underlying mechanism of risk score generation. Plans cannot code their way back to pre-reform revenue levels because the coding pathways that generated that revenue are being eliminated. The tightening is structural and permanent.

Third, the payvider model did not exist at meaningful scale during the ACA consolidation. Kaiser Permanente was the exception, not a replicable category. Today, UPMC, Geisinger, CareOregon, and the national carriers’ delivery system investments (Optum Health, CenterWell, Oak Street) represent a payvider tier that can absorb enrollment from departing standalone insurers in ways that were not available during the ACA period. The post-consolidation market may restructure not just around fewer plans but around a different organizational form.

Current Exit Signals

#

The market data from the 2026 cycle provides early indicators of where exit and contraction are concentrating.

UnitedHealth projected a loss of 1.3 to 1.4 million MA members for 2026 through targeted plan exits and benefit reductions. The company’s county-by-county withdrawal decisions reflected a portfolio optimization logic: exit counties where the benchmark, utilization, and competitive dynamics produced negative margin, and concentrate resources in geographies where the math still works. The counties UnitedHealth exited tend to cluster in low-benchmark rural areas and in markets where the company’s Star Ratings on specific contracts did not qualify for QBP.

Seven states saw MA enrollment decline during the 2026 AEP, including Vermont (complete market exit by Blue Cross Vermont), Wyoming, New Hampshire, Idaho, Minnesota, Maryland, and South Dakota. In several of these states, the enrollment decline reflected specific carrier decisions rather than broad market rejection: UCare exited the non-SNP market in Minnesota, and UnitedHealth and Aetna significantly retreated from Maryland. Molina Healthcare announced a complete exit from traditional MA by 2027. The total number of distinct MA plan offerings fell from 5,578 in 2025 to approximately 5,565 in 2026, with non-SNP offerings declining 8.6% while SNP offerings increased 19%. The shift from non-SNP to SNP reflects plans’ strategic reallocation toward dual eligible and chronic condition populations where risk scores and per-capita revenue are higher.

AEP 2026 produced the weakest enrollment growth in over a decade, with MA adding only approximately 110,000 net new enrollees, a 0.3% increase compared to growth rates of 4% to 8% in prior years. The growth slowdown is a leading indicator: it reflects the carrier decisions on benefit design, market footprint, and marketing investment that are the operational expression of rate compression. Plans that cut benefits and exited counties for 2026 produced the enrollment stagnation. Plans preparing 2027 bids at 0.09% will make similar or more aggressive decisions, meaning the 2027 AEP could produce the first absolute enrollment decline in MA’s modern history.

The VBID vacuum adds an innovation dimension to the exit dynamic. CMS ended the Value-Based Insurance Design demonstration in December 2024, removing the only active CMMI model operating inside Medicare Advantage. VBID had allowed participating plans to test supplemental benefit innovations, including flexible benefit structures for chronically ill enrollees and reduced cost-sharing for high-value services. With VBID terminated and no replacement model in place, MA plans have no CMMI-sponsored framework for testing benefit design innovations that might generate the evidence base for new supplemental benefit categories. The gap between CMMI’s FFS innovation agenda, which is producing WISeR, ACCESS, BALANCE, and AHEAD, and MA’s innovation needs is conspicuous. Plans that were using VBID to test approaches that could improve member outcomes while managing costs have lost both the regulatory flexibility and the evaluation infrastructure the demonstration provided.

Where New Entrants Could Emerge

#

National carrier exits create enrollment pools, and enrollment pools attract new entrants.

Health systems that already operate provider networks in markets where national carriers are retreating face a strategic opportunity to launch or expand provider-sponsored MA plans. A hospital system serving a community where UnitedHealth or Aetna exits can offer its patients MA coverage through a provider-sponsored plan that keeps them within the system’s care delivery infrastructure. The system captures both the insurance premium and the clinical revenue, creating the payvider economics that standalone insurers cannot replicate. The enrollment pool created by carrier exit is not a cold market; it is a population of beneficiaries actively seeking new MA coverage during a Special Enrollment Period, many of whom already receive care from local providers. A health system that can offer those beneficiaries an MA plan that includes their current doctors and hospitals has a compelling enrollment proposition (MCR-05.02).

The barriers to provider-sponsored plan entry are real but navigable. Launching an MA plan requires an insurance license, capital reserves, CMS contract approval, network adequacy demonstration, bid development capability, and enrollment and claims processing infrastructure. Health systems without insurance operations experience typically partner with or acquire existing plan infrastructure. The timeline from decision to operational plan is 12 to 24 months, meaning a system that begins planning in response to 2026 market exits would not have an operational plan until 2028 at the earliest. The window for capture is limited, and beneficiaries displaced in 2026 or 2027 will have enrolled in alternative coverage by the time a new provider-sponsored plan launches.

Tech-enabled plan models represent a second entrant category, though their track record in Medicare is mixed. Alignment Healthcare, Devoted Health, and Clover Health built MA business models around data analytics, AI-driven clinical decision support, and value-based care delivery infrastructure. The thesis, analogous to what Oscar Health attempted in commercial insurance, is that technology-driven cost management and operational efficiency can substitute for the coding-driven margin that rate compression removes. The results so far are inconclusive. Several tech-enabled MA entrants have struggled with profitability, and their enrollment bases remain small relative to national carriers. Devoted Health has grown rapidly in select markets but faces the same utilization and cost headwinds as legacy carriers. Alignment Healthcare has demonstrated clinical quality metrics in its California markets but has not scaled to a level where its model’s viability is established nationally. The question is whether these companies can survive the same rate compression that is forcing legacy carriers to retreat, given that their cost structures, while different in composition, are not necessarily lower in aggregate.

PACE expansion represents a structural entrant category specific to the dual eligible population. In markets where D-SNPs exit or reduce benefits, PACE organizations offer a more comprehensive alternative: full capitation covering Medicare and Medicaid benefits under a single organizational structure with an interdisciplinary care team model designed for the frailest beneficiaries. PACE enrollment nationally is approximately 75,000, a fraction of the dual eligible population, but the model has demonstrated per-beneficiary cost savings and clinical outcomes that justify expansion. The startup capital barrier for new PACE organizations is significant, requiring facility investment, staffing infrastructure, and state Medicaid agency approval. Whether the One Big Beautiful Bill Act’s Rural Health Transformation Program funding creates a pathway for PACE expansion in rural markets where D-SNPs are departing is an open question with policy implications for the dual eligible population’s coverage continuity (MCR-09.06).

M&A Landscape

#

Rate compression changes the strategic logic of MA plan acquisitions. The acquirer’s thesis depends on what the target provides that the acquirer lacks: Stars, provider relationships, geographic presence, delivery system capabilities, or enrollment scale.

A national carrier acquiring a regional nonprofit is typically buying Star Ratings and provider relationships. Regional nonprofits with stable 4-star or above ratings carry QBP revenue that the acquiring national carrier may not have in that market. The acquisition gives the national carrier access to the quality bonus without the multi-year investment required to earn it organically. The risk is that the cultural and operational integration destroys the provider relationships and quality infrastructure that made the regional plan valuable. Star Ratings are contract-level, and a contract’s rating reflects its specific provider network, member population, and operational practices. Transplanting a regional nonprofit’s contract into a national carrier’s operating infrastructure may not preserve the rating.

Regional plans acquiring other regional plans pursue scale within a geographic market. Two regional nonprofits in adjacent markets can combine to spread administrative costs, strengthen provider network negotiating leverage, and diversify their enrollment base. The combinations make strategic sense when neither plan alone has sufficient scale to absorb rate compression but the combined entity does. The regulatory pathway for these combinations typically involves state insurance department approval and CMS contract consolidation, processes that take 6 to 12 months.

Health systems acquiring MA plan contracts to complete a payvider conversion represent the acquisition type most aligned with the structural direction of the market. A system with clinical delivery infrastructure and population health capabilities that lacks an insurance license and plan operational platform can acquire a small MA plan contract and migrate its patient population into the plan. The system gains capitated revenue and risk management experience; the plan gains a delivery system that reduces its dependence on external provider contracting. These conversions are the mechanism through which the ACO-to-payvider pipeline materializes at the organizational level (MCR-05.02).

PE-backed roll-ups in physician groups, home health, hospice, and post-acute care represent a different acquisition dynamic that intersects with MA consolidation. Private equity firms that have consolidated provider organizations in these segments now sit on platforms that could be repositioned as MA-adjacent delivery assets. A PE-owned physician group with 500 primary care doctors serving 200,000 Medicare patients is a potential payvider seed: it has the clinical relationships, encounter data, and population health infrastructure to support a provider-sponsored plan. Whether PE ownership is compatible with the mission-driven, quality-focused culture that payvider success requires is a question the evidence has not conclusively answered (MCR-04.11).

Regulatory considerations for MA plan acquisitions involve three review layers. CMS must approve the transfer of an MA contract from one organization to another, a process that includes evaluation of the acquiring entity’s operational capacity, network adequacy, and financial stability. State insurance departments review the transaction for solvency, consumer protection, and market concentration implications. In highly concentrated markets where a single plan already holds dominant share, antitrust review by the Department of Justice or Federal Trade Commission may be triggered if the acquisition would further reduce competition. The regulatory timeline means that acquisitions motivated by the CY 2027 rate environment will not produce operational results until CY 2028 or CY 2029, by which point the rate environment may have shifted again.

The MA market that emerges from the 2026-2028 consolidation cycle will be structurally different from the market that entered it. Fewer plans, more concentrated enrollment, greater payvider representation, expanded SNP and PACE presence in the dual eligible segment, and a competitive dynamic that rewards clinical integration over coding optimization. The plans that navigate the consolidation successfully are those that recognized, before the rate shock, that the growth-era operating model was temporary and that the organizations built for what comes next are different from the organizations built for what came before.

Related Reading

#

MCR-00_03 The Medigap Market MCR-02_06 State-by-State Rate Impact Analysis: Top 20 Markets MCR-12_01 The MA Plan Landscape Under Pressure: UnitedHealth, Humana, CVS/Aetna, Elevance, and the Regional Plans